Search

Your search keyword '"Kelly, Kara"' showing total 900 results
Start Over Author "Kelly, Kara"
900 results on '"Kelly, Kara"'

251. Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001

Author

Kahn, Justine, primary, Barrera, Sergio, additional, Davila, Randy, additional, Roberts, Emily, additional, Jin, ZheZhen, additional, Stevenson, Kristen, additional, Blonquist, Traci M., additional, Neuberg, Donna S, additional, Athale, Uma H., additional, Clavell, Luis A., additional, Cole, Peter, additional, Laverdiere, Caroline, additional, Michon, Bruno, additional, Schorin, Marshall A., additional, Welch, Jennifer J.G., additional, Sallan, Stephen E., additional, Silverman, Lewis B., additional, and Kelly, Kara M., additional

Published
2015
Full Text
View/download PDF

252. An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Author

Kelly, Michael J., primary, Parsons, Susan K, additional, Hodgson, David C., additional, Cohen, Joshua T, additional, Yeh, Jennifer M, additional, Abramson, Jeremy S., additional, Friedman, Debra L., additional, Henderson, Tara O, additional, Johnson, Peter W, additional, Pauker, Stephen G, additional, Raemaekers, John M., additional, Winter, Jane N., additional, Kelly, Kara M., additional, Meyer, Ralph M., additional, Castellino, Sharon M, additional, and Evens, Andrew M., additional

Published
2015
Full Text
View/download PDF

253. Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Author

Harris, Marian H., primary, Blonquist, Traci M., additional, Athale, Uma H., additional, Clavell, Luis A., additional, Cole, Peter D., additional, Kelly, Kara M., additional, Laverdiere, Caroline, additional, Leclerc, Jean-Marie, additional, Michon, Bruno, additional, Schorin, Marshall A., additional, Welch, Jennifer J.G., additional, Neuberg, Donna S., additional, Sallan, Stephen E., additional, and Silverman, Lewis B., additional

Published
2015
Full Text
View/download PDF

255. Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Author

Henderson, Tara O, primary, Parsons, Susan K, additional, Wroblewski, Kristen, additional, Chen, Lu, additional, Hong, Fangxin, additional, Smith, Sonali M., additional, McNeer, Jennifer, additional, Advani, Ranjana, additional, Gascoyne, Randy D., additional, Constine, Louis, additional, Horning, Sandra J, additional, Bartlett, Nancy L, additional, Shah, Bijal D., additional, Connors, Joseph M., additional, Leonard, John P., additional, Kahl, Brad S., additional, Kelly, Kara M., additional, Schwartz, Cindy, additional, Friedman, Debra L., additional, Gordon, Leo I., additional, and Evens, Andrew M., additional

Published
2015
Full Text
View/download PDF

256. Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Author

Sulis, Maria Luisa, primary, Blonquist, Traci M., additional, Athale, Uma H., additional, Clavell, Luis A., additional, Cole, Peter D., additional, Kelly, Kara M., additional, Laverdiere, Caroline, additional, Leclerc, Jean-Marie, additional, Michon, Bruno, additional, Schorin, Marshall A., additional, Welch, Jennifer J.G., additional, Neuberg, Donna S, additional, Sallan, Stephen E., additional, and Silverman, Lewis B., additional

Published
2015
Full Text
View/download PDF

258. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

Author

Place, Andrew E, primary, Stevenson, Kristen E, additional, Vrooman, Lynda M, additional, Harris, Marian H, additional, Hunt, Sarah K, additional, O'Brien, Jane E, additional, Supko, Jeffrey G, additional, Asselin, Barbara L, additional, Athale, Uma H, additional, Clavell, Luis A, additional, Cole, Peter D, additional, Kelly, Kara M, additional, Laverdiere, Caroline, additional, Leclerc, Jean-Marie, additional, Michon, Bruno, additional, Schorin, Marshall A, additional, Welch, Jennifer J G, additional, Lipshultz, Steven E, additional, Kutok, Jeffery L, additional, Blonquist, Traci M, additional, Neuberg, Donna S, additional, Sallan, Stephen E, additional, and Silverman, Lewis B, additional

Published
2015
Full Text
View/download PDF

260. Pediatric Hodgkin Lymphoma

Author

Mauz-Körholz, Christine, primary, Metzger, Monika L., additional, Kelly, Kara M., additional, Schwartz, Cindy L., additional, Castellanos, Mauricio E., additional, Dieckmann, Karin, additional, Kluge, Regine, additional, and Körholz, Dieter, additional

Published
2015
Full Text
View/download PDF

262. Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.

Author

Cole, Peter D., primary, Metzger, Monika, additional, Drachtman, Richard A., additional, Horton, Terzah M., additional, Liu, Xiaowei, additional, Ahern, Charlotte H., additional, Minard, Charles, additional, Fox, Elizabeth, additional, Blaney, Susan, additional, Weigel, Brenda, additional, and Kelly, Kara M., additional

Published
2015
Full Text
View/download PDF

263. Integrative tumor board: pediatric synovial sarcoma

Author

Granowetter, Linda, Ladas, Elena, Taromina, Kathy, Rooney, Diane, and Kelly, Kara M.

Subjects
Sarcoma -- Care and treatment, Integrative medicine -- Care and treatment, Health, Care and treatment
Abstract

Case Presentation Chief complaint: The patient is an 11-year-old boy diagnosed with a synovial sarcoma of the left jaw. History of the present illness The family of the patient sought [...]

Published
2006

264. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

Author

Vrooman, Lynda M., Supko, Jeffrey G., Neuberg, Donna S., Asselin, Barbara L., Athale, Uma H., Clavell, Luis, Kelly, Kara M., Laverdière, Caroline, Michon, Bruno, Schorin, Marshall, Cohen, Harvey J., Sallan, Stephen E., and Silverman, Lewis B.

Subjects
Adolescent, Infant, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survival Analysis, Article, Drug Administration Schedule, Drug Hypersensitivity, Child, Preschool, Escherichia coli, Asparaginase, Erwinia, Humans, Child
Abstract

Escherichia coli asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia (ALL); however, hypersensitivity develops in up to 30% of patients. We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase-allergic patients.Between 2000 and 2002, 215 children with newly diagnosed ALL were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 and were to receive 30 weekly doses of intramuscular E. coli asparaginase. If E. coli asparaginase allergy developed, patients were switched to twice-weekly intramuscular Erwinia asparaginase (25,000 IU/m(2)). Nadir serum asparaginase activity (NSAA) was measured every 3 weeks.Forty-two patients (20%) developed E. coli asparaginase allergy and switched to Erwinia. Of 38 patients with evaluable samples, 34 (89%) Erwinia-treated patients had at least one therapeutic NSAA (or =0.1 IU/ml). The median NSAA was 0.247 IU/ml 3 days and 0.077 IU/ml 4 days after an Erwinia dose. Associated toxicities included allergy in 14 (33%) and pancreatitis in 3 patients (7%). At a median follow-up of 5.4 years, event-free survival (+/-standard error) of the 42 patients who switched to Erwinia was 86 +/- 5% compared with 81 +/- 3% for the 170 patients without E. coli asparaginase allergy (P = 0.55).Twice-weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase-allergic patients. Development of E. coli allergy and subsequent treatment with twice-weekly Erwinia did not adversely impact event-free survival. Erwinia asparaginase should be considered for E. coli asparaginase-allergic patients.

Published
2009

266. Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Author

Kelly, Kara M., Ladas, Elena, Blonquist, Traci M., Stevenson, Kristen E., Lin, Meiko, Cole, Peter D, Orjuela, Manuela, Athale, Uma, Clavell, Luis A., Laverdière, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Schorin, Marshall A., Sulis, Maria Luisa, Welch, Jennifer J.G., Asselin, Barbara L, Sallan, Stephen E., and Silverman, Lewis B.

Published
2017
Full Text
View/download PDF

267. Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Author

Athale, Uma H., Blonquist, Traci M., Stevenson, Kristen E., Spira, Menachem, Cole, Peter D., Asselin, Barbara L, Clavell, Luis A., Kelly, Kara M., Laverdière, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Schorin, Marshall A., Sulis, Maria Luisa, Welch, Jennifer J.G., Harris, Marian H., Neuberg, Donna S., Sallan, Stephen E., and Silverman, Lewis B.

Published
2017
Full Text
View/download PDF

270. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Author

Henderson, Tara O., Parsons, Susan K., Wroblewski, Kristen E., Chen, Lu, Hong, Fangxin, Smith, Sonali M., McNeer, Jennifer L., Advani, Ranjana H., Gascoyne, Randy D., Constine, Louis S., Horning, Sandra, Bartlett, Nancy L., Shah, Bijal, Connors, Joseph M., Leonard, John I., Kahl, Brad S., Kelly, Kara M., Schwartz, Cindy L., Li, Hongli, and Friedberg, Jonathan W.

Subjects
HODGKIN'S disease, HODGKIN'S disease treatment, COMPARATIVE method, QUALITY of life, ONCOLOGY, PATIENTS, ANTINEOPLASTIC agents, VINBLASTINE, DACARBAZINE, BLEOMYCIN, DOXORUBICIN, ETOPOSIDE, MEDIASTINAL tumors, PREDNISONE, PROGNOSIS, RADIOTHERAPY, SURVIVAL, TUMOR classification, VINCRISTINE, TREATMENT effectiveness, RETROSPECTIVE studies, CYCLOPHOSPHAMIDE, TUMOR treatment, THERAPEUTICS
Abstract

Background: There is no clear consensus between pediatric and adult providers about the treatment of adolescents and young adults (AYAs) with Hodgkin lymphoma (HL).Methods: Failure-free survival (FFS) and overall survival (OS) were compared between 114 patients ages 17 to 21 years with HL who were treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult E2496 study and 391 similarly patients ages 17 to 21 years with HL who were treated on the pediatric Children's Oncology Group (COG) AHOD0031 study.Results: Comparing AYAs from the COG and E2496 studies, there were no significant differences in extralymphatic disease, anemia, or hypoalbuminemia. More AYAs in the E2496 trial had stage III and IV disease (63% vs 29%; P < .001) and B symptoms (63% vs 27%; P < .001), and fewer had bulk disease (33% vs 77%; P < .001). More AYAs on the COG trial received radiotherapy (76% vs 66%; P = .03), although in smaller doses. E2496 AYA The 5-year FFS and OS rates were 68% and 89%, respectively in the E2496 AYAs and 81% and 97%, respectively, in the COG AYAs, indicating a statistically superior compared in the COG AYAs (P = .001). In stratified multivariable analyses, E2496 AYAs had worse FFS than COG AYAs in all strata except patients who had stage I and II HL without anemia. Propensity score analysis (based on stage, anemia, and bulk disease) confirmed inferior FFS for E2496 AYAs compared with COG AYAs (P = .004). On the E2496 study, FFS was significantly divergent across age groups (P = .005), with inferior outcomes for those ages 17 to 21 years versus 22-44 years. There was no difference across age on the COG study.Conclusions: Younger AYA patients with HL appear to have better outcomes when treated on a pediatric trial than patients of similar age on an adult trial. Prospective studies examining these differences are warranted. Cancer 2018;124:136-44. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

272. Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Author

Diefenbach, Catherine S., Connors, Joseph M., Friedberg, Jonathan W., Leonard, John P., Kahl, Brad S., Little, Richard F., Baizer, Lawrence, Evens, Andrew M., Hoppe, Richard T., Kelly, Kara M., Persky, Daniel O., Younes, Anas, Kostakaglu, Lale, and Bartlett, Nancy L.

Subjects
HODGKIN'S disease, CLINICAL trials, CANCER in young adults, INVESTIGATIONAL therapies, QUALITY of life, ANTINEOPLASTIC agents, BIOLOGICAL assay, RESEARCH funding
Abstract

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

273. Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia.

Author

Sands, Stephen, Harel, Brian, Savone, Mirko, Kelly, Kara, Vijayanathan, Veena, Welch, Jennifer, Vrooman, Lynda, Silverman, Lewis, Cole, Peter, Sands, Stephen A, Harel, Brian T, Welch, Jennifer Greene, Silverman, Lewis B, and Cole, Peter D

Subjects
LEUKEMIA in children, COGNITIVE Abilities Test, CEREBROSPINAL fluid examination, CANCER chemotherapy, BIOMARKERS, LEUKEMIA treatment, COGNITION disorders diagnosis, ANTINEOPLASTIC agents, ATTENTION, COGNITION, COGNITION disorders, COMPARATIVE studies, SPINAL injections, LYMPHOBLASTIC leukemia, RESEARCH methodology, MEDICAL cooperation, MEMORY, RESEARCH, RESEARCH funding, EVALUATION research, EXECUTIVE function, PSYCHOLOGY
Abstract

Purpose: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions.Methods: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial.Results: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges.Conclusions: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

274. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Author

Herrera, Alex Francisco, LeBlanc, Michael Leo, Castellino, Sharon M., Li, Hongli, Rutherford, Sarah C., Evens, Andrew M., Davison, Kelly, Punnett, Angela, Hodgson, David C., Parsons, Susan K., Ahmed, Sairah, Casulo, Carla, Bartlett, Nancy L., Song, Joo Y, Little, Richard F., Kahl, Brad S., Leonard, John Paul, Kelly, Kara M, Smith, Sonali M., and Friedberg, Jonathan W.

Published
2023
Full Text
View/download PDF

275. Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic...

Author

Harker-Murray, Paul David, Cole, Peter D., Hoppe, Bradford S., Hodgson, David C., Beishuizen, Auke, Garnier, Nathalie, Buffardi, Salvatore, Mascarin, Maurizio, Lissat, Andrej, Akyol, Alev, Crowe, Russell, Li, Ju, Drachtman, Richard A., Kelly, Kara M, Leblanc, Thierry, and Daw, Stephen

Published
2023
Full Text
View/download PDF

276. Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Author

Rodday, Angie Mae, Parsons, Susan K, Scharman, Carlton, Advani, Ranjana, Federico, Massimo, Friedberg, Jonathan W., Gallamini, Andrea, Hodgson, David C., Hoskin, Peter, Hutchings, Martin, Johnson, Peter, Kelly, Kara M., Link, Brian K., Radford, John A., Zinzani, Pier Luigi, Cerhan, James R., Raemaekers, John, Evens, Andrew M., and HoLISTIC Consortium, On Behalf Of The

Abstract

Background:While HL is a highly curable cancer, patients (pts) with advanced stage disease experience increased risk of relapse. Delineation of prognosis is desired to compare cohorts and outcomes between trials, and to define groups of pts for whom reduction in treatment may be appropriate or where novel therapeutic approaches are needed. The International Prognostic Score (IPS), which was derived from a discovery set of 1,618 HL pts with complete data, was a seminal publication in the field (Hasenclever and Diehl NEJM1998). However, these data were published >20 years ago with a significant minority of pts having received chemotherapy regimens no longer in clinical use. More contemporary analyses have shown altered utility of the IPS (e.g., Moccia JCO2012; Diefenbach BJH2015). In addition, prior studies identified bulk disease as an adverse prognostic factor in advanced stage HL (Laskar JCO2004; Johnson JCO2010). Our objective was to leverage individual pt data (IPD) from HoLISTIC (www.hodgkinconsortium.com)to discover a new, robust, and modern prognostication index for advanced-stage HL pts applicable to diverse settings across the world.

Published
2020
Full Text
View/download PDF

277. Traditional Complementary/Alternative Medicine Survey

Author

Ladas, Elena J., primary, Lin, Meiko, additional, Antillion, Federico, additional, Rivas, Silvia, additional, Chantada, Guillermo, additional, Cacciavillano, Walter, additional, Ortiz, Roberta, additional, Stein, Katja, additional, Castillo, Luis, additional, Rocha, Valeria, additional, Fu, Ligia, additional, Rodriquez, Hilze, additional, and Kelly, Kara M., additional

Published
2015
Full Text
View/download PDF

278. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia

Author

Silverman, Lewis B., Supko, Jeffrey G., Stevenson, Kristen E., Woodward, Christina, Vrooman, Lynda M., Neuberg, Donna S., Asselin, Barbara L., Athale, Uma H., Clavell, Luis, Cole, Peter D., Kelly, Kara M., Laverdière, Caroline, Michon, Bruno, Schorin, Marshall, Schwartz, Cindy L., O'Brien, Jane E., Cohen, Harvey J., and Sallan, Stephen E.

Published
2010
Full Text
View/download PDF

279. Improving our understanding of the use of traditional complementary/alternative medicine in children with cancer

Author

Ladas, Elena J., primary, Lin, Meiko, additional, Antillion, Federico, additional, Rivas, Silvia, additional, Chantada, Guillermo, additional, Cacciavillano, Walter, additional, Ortiz, Roberta, additional, Stein, Katja, additional, Castillo, Luis, additional, Rocha, Valeria, additional, Fu, Ligia, additional, Rodriquez, Hilze, additional, and Kelly, Kara M., additional

Published
2014
Full Text
View/download PDF

284. Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001.

Author

Place, Andrew E., primary, Stevenson, Kristen E., additional, Harris, Marian H., additional, Weinberg, Olga K., additional, Vrooman, Lynda M., additional, Hunt, Sarah K., additional, Ahmed, Samia S., additional, Athale, Uma H., additional, Clavell, Luis Antonio, additional, Cole, Peter D., additional, Kelly, Kara M., additional, Laverdiere, Caroline, additional, Leclerc, Jean-Marie, additional, Michon, Bruno, additional, Schorin, Marshall A., additional, Welch, Jennifer JG, additional, Asselin, Barbara, additional, Neuberg, Donna S., additional, Sallan, Stephen E., additional, and Silverman, Lewis B., additional

Published
2014
Full Text
View/download PDF

285. Hepatic Stellate Cells Orchestrate Clearance of Necrotic Cells in a Hypoxia-Inducible Factor-1α–Dependent Manner by Modulating Macrophage Phenotype in Mice

Author

Mochizuki, Akie, primary, Pace, Aaron, additional, Rockwell, Cheryl E., additional, Roth, Katherine J., additional, Chow, Aaron, additional, O’Brien, Kate M., additional, Albee, Ryan, additional, Kelly, Kara, additional, Towery, Keara, additional, Luyendyk, James P., additional, and Copple, Bryan L., additional

Published
2014
Full Text
View/download PDF

286. Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol

Author

Rae, Charlene, Furlong, William, Feeny, David, Couchman, Rana, Silverman, Lewis, Sallan, Stephen, Laverdiere, Caroline, Clavell, Luis, Michon, Bruno, Kelly, Kara, Larsen, Eric, Pullenayegum, Eleanor, Athale, Uma, and Barr, Ronald

Abstract

Health-related quality of life (HRQL) improved progressively during therapy and beyond in children treated for acute lymphoblastic leukemia on the Dana-Farber Cancer Institute (DFCI) 95-01 protocol. This study aimed to validate that trajectory in a successor study (DFCI 00-01) and to compare the HRQL of patients in the 2 studies. Children aged above 5 years were assessed during each phase of treatment (N=4) and 2 years after completion of therapy. Health status and HRQL were measured using Health Utilities Index (HUI) instruments, HUI2 and HUI3. Quality-adjusted life years (QALYs) were calculated and compared with the general population, and patients treated on DFCI 95-01. Over 5 intervals and 758 HUI assessments, mean HRQL increased progressively from remission induction to the time after treatment (P<0.001). During intensification, high-risk patients had lower HRQL than standard-risk patients (P<0.001). During remission induction, patients on DFCI 95-01 had lower HRQL than patients on DFCI 00-01. Patients on DFCI 00-01 had ~0.2 and 0.3 fewer QALYs than controls, measured by HUI2 and HUI3, respectively. QALYs for DFCI 00-01 patients during treatment were similar to those for DFCI 95-01 patients. The trajectory of improvement in HRQL during the treatment of acute lymphoblastic leukemia in children was confirmed.

Published
2018
Full Text
View/download PDF

287. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001

Author

Vrooman, Lynda M., Blonquist, Traci M., Harris, Marian H., Stevenson, Kristen E., Place, Andrew E., Hunt, Sarah K., O’Brien, Jane E., Asselin, Barbara L., Athale, Uma H., Clavell, Luis A., Cole, Peter D., Kelly, Kara M., Laverdiere, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Schorin, Marshall A., Sulis, Maria Luisa, Welch, Jennifer J. G., Neuberg, Donna S., Sallan, Stephen E., and Silverman, Lewis B.

Abstract

Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001 tested a new risk stratification system in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL). At study entry, B-ALL patients were classified as standard risk (SR) or high risk (HR) based on age, white blood cell (WBC) count, and central nervous system status. After achieving complete remission (CR), patients with high end-induction minimal residual disease (MRD) (=10-3 by polymerase chain reaction analysis of patient-specific antigen receptor rearrangements) and/or adverse cytogenetics (KMT2A rearrangement or hypodiploidy) were reclassified as very high risk (VHR) and received intensified therapy. IKZF1 deletion status was retrospectively evaluated by multiplex ligation-dependent probe amplification. Between 2005 and 2011, 678 Philadelphia chromosome-negative B-ALL patients aged 1 to 18 years enrolled; 651 achieved CR and 648 received a final risk group. Among all 678 patients, 5-year event-free survival (EFS) was 87% (95% confidence interval [CI], 84-89) and overall survival 93% (95% CI, 90-94). Five-year disease-free survival of SR patients (N = 407) was 94% (95% CI, 91-96), HR (N = 176) was 84% (95% CI, 77-88), and VHR (N = 65) was 79% (95% CI, 67-87). IKZF1 deletion was present in 62 of 385 (16%) assessed patients and was associated with inferior 5-year EFS (63%; 95% CI, 49%-74% vs 88%; 95% CI, 84%-91%; P < .001), and higher 5-year cumulative incidence of relapse, including among those with low MRD (24% vs 8%, P = .001). In multivariable analysis, age =15 years, WBC =50?× 109/L, IKZF1 deletion, and MRD =10-4 was each associated with inferior outcome. In conclusion, risk-stratified therapy on DFCI 05-001 resulted in favorable outcomes for B-ALL patients, including those with VHR features. IKZF1 deletion was an independent predictor of inferior outcome. This trial was registered at www.clinicaltrials.gov as #NCT00400946.

Published
2018
Full Text
View/download PDF

288. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia

Author

Tran, Thai Hoa, Harris, Marian H., Nguyen, Jonathan V., Blonquist, Traci M., Stevenson, Kristen E., Stonerock, Eileen, Asselin, Barbara L., Athale, Uma H., Clavell, Luis A., Cole, Peter D., Kelly, Kara M., Laverdiere, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Schorin, Marshall A., Welch, Jennifer J. G., Reshmi, Shalini C., Neuberg, Donna S., Sallan, Stephen E., Loh, Mignon L., and Silverman, Lewis B.

Abstract

Recurrent chromosomal rearrangements carry prognostic significance in pediatric B-lineage acute lymphoblastic leukemia (B-ALL). Recent genome-wide analyses identified a high-risk B-ALL subtype characterized by a diverse spectrum of genetic alterations activating kinases and cytokine receptor genes. This subtype is associated with a poor prognosis when treated with conventional chemotherapy but has demonstrated sensitivity to the relevant tyrosine kinase inhibitors. We sought to determine the frequency of kinase-activating fusions among National Cancer Institute (NCI) high-risk, Ph-negative, B-ALL patients enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 and to describe their associated clinical characteristics and outcomes. Among the 105 patients screened, 16 (15%) harbored an ABL-class fusion (ETV6-ABL1: n = 1; FOXP1-ABL1: n = 1; SFPQ-ABL1: n = 1; ZC3HAV1-ABL2: n = 1) or a fusion activating the JAK-STAT pathway (P2RY8-CRLF2: n = 8; PAX5-JAK2: n = 4). Sixty-nine percent of patients with an identified fusion had a concomitant IKZF1 deletion (n = 11). In univariate analysis, fusion-positivity and IKZF1 deletion were each associated with inferior event-free survival; IKZF1 deletion retained statistical significance in multivariable analysis (hazard ratio, 2.64; P = .019). Our findings support therapy intensification for IKZF1-altered patients, irrespective of the presence of a kinase-activating fusion.

Published
2018
Full Text
View/download PDF

291. Contributors

Author

Abrams, Ross A., Adelstein, David J., Alektiar, Kaled M., Alexander, Brian, Alsner, Jan, Altun, Ersan, Anderson, Bethany, Ang, K. Kian, Arthur, Douglas W., Ashman, Jonathan B., Ballo, Matthew T., Barker, Christopher Andrew, Beadle, Beth M., Bedard, Phillipe, Beitler, Jonathan J., Bishop, Michael W., Blackstock, A. William, Jr., Bogart, Jeffrey A., Bonner, James A., Bourland, J. Daniel, Bovi, Joseph, Breneman, John, Brito, Juan P., Brown, Paul D., Brundage, Michael D., Buchholz, Thomas A., Burmeister, Bryan Henry, Calderwood, Stuart K., Callister, Matthew D., Calvo, Felipe A., Cannon, George M., Chabner, Bruce A., Chan, Michael D., Chao, Sam T., Charpentier, Anne-Marie, Chung, Christine H., Chung, Peter W.M., Constine, Louis S., Corn, Benjamin W., Covens, Allan, Craciunescu, Oana I., Crane, Christopher H., Creutzberg, Carien L., Crook, Juanita M., Curran, Walter J., Jr., Czito, Brian G., Dabaja, Bouthaina S., Das, Shiva, David, Marc, Dawson, Laura A., DeLaney, Thomas F., Devlin, Phillip M., Dewhirst, Mark, Dizon, Don S., Dome, Jeffrey S., Donohue, John H., Duprez, Thierry P., Efstathiou, Jason A., Eisbruch, Avraham, Eisele, David W., Feng, Mary, Fernandes, Rui P., Fielding, Julia R., Fleming, Gini F., Foote, Robert L., Fraass, Benedick A., Freeman, Carolyn R., Garden, Adam S., Gentry, Lindell R., Gien, Lilian T., Gospodarowicz, Mary K., Grau, Cai, Grégoire, Vincent, Greven, Craig M., Greven, Kathryn McConnell, Gunderson, Leonard L., Haddock, Michael G., Halyard, Michele, Hamoir, Marc, Hanna, Timothy Paul, Harari, Paul M., Hay, Ian D., Herman, Joseph M., Holloway, Caroline L., Hong, Theodore Sunki, Horowitz, Neil S., Horseman, Michael R., Howle, Julie, Hrycushko, Brian A., Hsu, David, Hudgins, Patricia A., Hutchinson, Ryan C., Iacobuzio-Donahue, Christine, Izar, Benjamin, Jewells, Valerie L., Jurcic, Joseph Gerard, Kalapurakal, John A., Kavanagh, Brian D., Kelly, Kara M., Khandani, Amir H., Khuntia, Deepak, Kiess, Ana Ponce, Knox, Susan J., Koh, Wui-Jin, Krasin, Matthew J., Kun, Larry E., Laack, Nadia Issa, LaCasce, Ann S., Langer, Corey Jay, Laramore, George E., Lassman, Andrew B., Lawton, Colleen A.F., Lee, Nancy, Lengelé, Benoît, Levin, William P., Lindegaard, Jacob C., Lucas, John T., Jr., MacDonald, Shannon M., Mackillop, William J., Mahindra, Anuj, Mancuso, Anthony A., Marcus, Karen Jean, Marks, Lawrence B., Matceyevsky, Diana, Mazeron, Jean-Jacques, McDonald, Mark W., Medin, Paul M., Mehta, Minesh P., Mendenhall, William M., Meredith, Ruby F., Michalski, Jeff M., Milano, Michael T., Minsky, Bruce D., Morrison, William H., Murphy, Erin S., Murthy, Rashmi K., Ng, Andrea K., Nordsmark, Marianne, O'Farrell, Desmond A., Okunieff, Paul, Ove, Roger, Overgaard, Jens, Palta, Manisha, Parker, Alexander S., Pater, Luke E., Peterson, Jennifer L., Pisansky, Thomas M., Potters, Louis, Quon, Harry, Raben, David, Recht, Abram, Rengan, Ramesh, Reyngold, Marsha, Laufer, Riaz, Nadeem, Roberts, Stephen S., Roberts, Kenneth B., Rockhill, Jason K., Rödel, Claus M., Rodriguez-Galindo, Carlos, Rogers, C. Leland, Rosenblat, Todd L., Rule, William G., Russell, Anthony Henryk, Russo, Suzanne, Ryan, David P., Sandlund, John Torsten, Jr., Sandow, Pamela L., Sargent, Daniel J., Schild, Steven E., Seegenschmiedt, Michael Heinrich, Shah, Chirag, Shaw, Edward G., Sheehan, Jason P., Sheikh, Arif, Shi, Qian, Siker, Malika L., Small, William, Jr., Smith, Benjamin D., Smith, Grace L., Solberg, Timothy D., Stauffer, Paul R., Stevenson, Mary Ann, Stewart, Alexandra J., Suh, John H., Tan, Winston W., Tepper, Joel E., Thomas, Charles R., Jr., Thomas, Gillian M., Timmerman, Robert D., Tsang, Richard W., Usuki, Kenneth Y., Valentini, Vincenzo, Valero, Vicente, van den Bent, Martin J., Veness, Michael J., Vicini, Frank A., Vicus, Danielle, Viswanathan, Akila N., Vujaskovic, Zeljko, Wadsworth, J. Trad, Wagner, Henry, Jr., Wahl, Daniel R., Warde, Padraig R., Waxweiler, Timothy V., Wehle, Michael J., Weil, Robert J., Weiss, Lawrence M., Werning, John W., Willett, Christopher G., Willey, Christopher Douglas, Wilson, Lynn D., Winkfield, Karen M., Yon-Li, Jennifer, Wolden, Suzanne L., Wong, Terence Z., Wong, Jeffrey Y.C., Wong, William W., Wu, Wenting, Yahalom, Joachim, Yang, Eddy Shih-Hsin, You, Y. Nancy, Zeman, Elaine M., Zeng, Jing, and Zietman, Anthony L.

Published
2016
Full Text
View/download PDF

292. Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL

Author

Silverman, Lewis B., primary, Stevenson, Kristen E., additional, Athale, Uma H., additional, Clavell, Luis A., additional, Cole, Peter, additional, Kelly, Kara A., additional, Leclerc, Jean-Marie, additional, Michon, Bruno, additional, Schorin, Marshall A., additional, Schwartz, Cindy L, additional, Asselin, Barbara, additional, Supko, Jeffrey G, additional, Hunt, Sarah, additional, Andrew, Place, additional, Vrooman, Lynda M., additional, Neuberg, Donna S., additional, and Sallan, Stephen E., additional

Published
2013
Full Text
View/download PDF

294. Genetic loss of SH2B3 in acute lymphoblastic leukemia

Author

Perez-Garcia, Arianne, primary, Ambesi-Impiombato, Alberto, additional, Hadler, Michael, additional, Rigo, Isaura, additional, LeDuc, Charles A., additional, Kelly, Kara, additional, Jalas, Chaim, additional, Paietta, Elisabeth, additional, Racevskis, Janis, additional, Rowe, Jacob M., additional, Tallman, Martin S., additional, Paganin, Maddalena, additional, Basso, Giuseppe, additional, Tong, Wei, additional, Chung, Wendy K., additional, and Ferrando, Adolfo A., additional

Published
2013
Full Text
View/download PDF

296. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

Author

Lipshultz, Steven E., primary, Lipsitz, Stuart R., additional, Kutok, Jeffery L., additional, Miller, Tracie L., additional, Colan, Steven D., additional, Neuberg, Donna S., additional, Stevenson, Kristen E., additional, Fleming, Mark D., additional, Sallan, Stephen E., additional, Franco, Vivian I., additional, Henkel, Jacqueline M., additional, Asselin, Barbara L., additional, Athale, Uma H., additional, Clavell, Luis A., additional, Michon, Bruno, additional, Laverdiere, Caroline, additional, Larsen, Eric, additional, Kelly, Kara M., additional, and Silverman, Lewis B., additional

Published
2013
Full Text
View/download PDF

297. A Phase I Dose-Finding Study of Silybin Phosphatidylcholine (Milk Thistle) in Patients With Advanced Hepatocellular Carcinoma

Author

Siegel, Abby B., primary, Narayan, Rupa, additional, Rodriguez, Rosa, additional, Goyal, Abhishek, additional, Jacobson, DrPH, Judith S., additional, Kelly, Kara, additional, Ladas, Elena, additional, Lunghofer, Paul J., additional, Hansen, Ryan J., additional, Gustafson, Daniel L., additional, Flaig, Thomas W., additional, Yann Tsai, Wei, additional, Wu, David P. H., additional, Lee, Valerie, additional, and Greenlee, Heather, additional

Published
2013
Full Text
View/download PDF

299. Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

Author

Vrooman, Lynda M., primary, Stevenson, Kristen E., additional, Supko, Jeffrey G., additional, O'Brien, Jane, additional, Dahlberg, Suzanne E., additional, Asselin, Barbara L., additional, Athale, Uma H., additional, Clavell, Luis A., additional, Kelly, Kara M., additional, Kutok, Jeffery L., additional, Laverdière, Caroline, additional, Lipshultz, Steven E., additional, Michon, Bruno, additional, Schorin, Marshall, additional, Relling, Mary V., additional, Cohen, Harvey J., additional, Neuberg, Donna S., additional, Sallan, Stephen E., additional, and Silverman, Lewis B., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results